Tuesday, May 21, 2013 Last update: 5:35 AM
Company Tech News as it Breaks
Trade Events
CytRx Corporation
News articles for CytRx Corporation:
Monday, May 20, 2013
- CytRx Issues Letter to Stockholders Providing Business UpdateCytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, announced the issuance of its annual Letter to Stockholders from ... read more
Thursday, May 9, 2013
- CytRx Reports 2013 First Quarter Financial ResultsCytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended ... read more
Wednesday, May 8, 2013
- CytRx Provides Update on Clinical ProgramsCytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will focus on the clinical ... read more
Monday, May 6, 2013
- CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete International Phase 2b Trial with Aldoxorubicin as First-Line Treatment for Soft Tissue SarcomaCytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, announced that the independent Data Safety Monitoring Committee (DSMC) overseeing ... read more
Tuesday, March 12, 2013
- CytRx to Present at the 25th Annual ROTH ConferenceCytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that President and CEO Steven A. Kriegsman and ... read more
Monday, March 11, 2013
- CytRx Reports 2012 Financial ResultsCytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the 12 months ended December ... read more
Friday, March 1, 2013
- CytRx to Present at the Cowen & Company 33rd Annual Health Care ConferenceCytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that Vice President of Business Development David J. Haen will ... read more
Thursday, February 28, 2013
- CytRx Reaches Patient Enrollment Target in Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung CancerCytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that enrollment of 140 evaluable patients has been ... read more
Wednesday, February 6, 2013
- CytRx to Present at the 2013 Leerink Swann Global Healthcare ConferenceCytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that President and CEO Steven A. Kriegsman and ... read more
Monday, February 4, 2013
- CytRx to Present at the BIO CEO & Investor ConferenceCytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that President and Chief Executive Officer Steven A. ... read more
Thursday, January 31, 2013
- CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung CancerCytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that the Data Safety Monitoring Committee overseeing the ... read more
Monday, January 28, 2013
- CytRx Announces Positive Results from Animal Trial with Combination Aldoxorubicin and Doxorubicin TherapyCytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that an in vivo trial investigating aldoxorubicin, its ... read more
Thursday, January 3, 2013
- CytRx Promotes Dr. Daniel Levitt to Executive Vice PresidentCytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, has named Daniel Levitt, M.D., Ph.D., to the newly ... read more
Wednesday, January 2, 2013
- CytRx to Present at the Biotech Showcase 2013 ConferenceCytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that President and CEO Steven A. Kriegsman and ... read more